Sort   by:  
 Page size 
GenomicsThe Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer world-wide with 1.2 million patients diagnosed yearly. In late stage CRC, the most commonly used targeted therapies are monoclonal antibodies cetuximab and panitumumab, which inactivate EGFR. Recent studies have identified alterations in KRAS...
EGAS00001001305 | EGA
Genomicsena-DATASET-JHUSM-28-09-2015-22:11:53:244-560 - samples
Description not provided
EGAD00001001628 | EGA
Genomicsena-DATASET-JHUSM-16-11-2015-19:53:19:325-4 - samples
Description not provided
EGAD00001001674 | EGA
GenomicsDAC for the study of response to EGFR Blockade in Colorectal Cancer
Data Access Committee EGAC00001000360
EGAC00001000360 | EGA
ProteomicsCPTAC CCRCC Discovery Study - DIA Proteome
This is a supplementary study to the CPTAC CCRCC Discovery Study - Proteome. Unlabeled, digested peptide material from individual tissue samples (ccRCC and NAT) was spiked with index Retention Time (iRT) peptides (Biognosys) and subjected to data-independent acquisition (DIA) analysis. Kidney cance...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2023-10-04 | MSV000093041 | MassIVE
Sort   by:  
 Page size